Literature DB >> 15932513

Growth factor deficiency in patients with ataxia telangiectasia.

R Schubert1, J Reichenbach, S Zielen.   

Abstract

One prominent feature of patients with the autosomal recessive disease ataxia telangiectasia (AT) is somatic growth retardation. Due to their essential roles in development we examined levels of insulin-like growth factor-I (IGF-I) as well as its main binding protein (IGFBP-3) in a group of AT patients. Growth status of 19 patients was assessed by body mass index (BMI) and nutritional protocols. As suspected, BMI was low in AT patients despite adequate nutrition. Serum levels of IGF-I were found to be below the 3rd percentile in 9 (56%) out of 16 patients and of IGFBP-3 in 13 (81%) out of 16 patients. Our observations demonstrate that IGF-I and IGFBP-3 levels reflect the impaired growth status in patients with AT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15932513      PMCID: PMC1809398          DOI: 10.1111/j.1365-2249.2005.02782.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  8 in total

Review 1.  The thymic insulin-like growth factor axis: involvement in physiology and disease.

Authors:  V Geenen
Journal:  Horm Metab Res       Date:  2003 Nov-Dec       Impact factor: 2.936

Review 2.  Radioimmunoassays for IGFs and IGFBPs.

Authors:  W F Blum; B H Breier
Journal:  Growth Regul       Date:  1994-02

Review 3.  Normal values of insulin-like growth factor I and their clinical utility in adults.

Authors:  C J Strasburger; M Bidlingmaier; Z Wu; K M Morrison
Journal:  Horm Res       Date:  2001

4.  Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1.

Authors:  D Q Yang; M B Kastan
Journal:  Nat Cell Biol       Date:  2000-12       Impact factor: 28.824

5.  Neurodegeneration is associated to changes in serum insulin-like growth factors.

Authors:  S Busiguina; A M Fernandez; V Barrios; R Clark; D L Tolbert; J Berciano; I Torres-Aleman
Journal:  Neurobiol Dis       Date:  2000-12       Impact factor: 5.996

Review 6.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis.

Authors:  Andrew G Renehan; Marcel Zwahlen; Christoph Minder; Sarah T O'Dwyer; Stephen M Shalet; Matthias Egger
Journal:  Lancet       Date:  2004-04-24       Impact factor: 79.321

7.  Atm-deficient mice: a paradigm of ataxia telangiectasia.

Authors:  C Barlow; S Hirotsune; R Paylor; M Liyanage; M Eckhaus; F Collins; Y Shiloh; J N Crawley; T Ried; D Tagle; A Wynshaw-Boris
Journal:  Cell       Date:  1996-07-12       Impact factor: 41.582

8.  ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response.

Authors:  S Peretz; R Jensen; R Baserga; P M Glazer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

  8 in total
  12 in total

1.  A novel porcine model of ataxia telangiectasia reproduces neurological features and motor deficits of human disease.

Authors:  Rosanna Beraldi; Chun-Hung Chan; Christopher S Rogers; Attila D Kovács; David K Meyerholz; Constantin Trantzas; Allyn M Lambertz; Benjamin W Darbro; Krystal L Weber; Katherine A M White; Richard V Rheeden; Michael C Kruer; Brian A Dacken; Xiao-Jun Wang; Bryan T Davis; Judy A Rohret; Jason T Struzynski; Frank A Rohret; Jill M Weimer; David A Pearce
Journal:  Hum Mol Genet       Date:  2015-09-15       Impact factor: 6.150

2.  Endocrine abnormalities in ataxia telangiectasia: findings from a national cohort.

Authors:  Andreea Nissenkorn; Yael Levy-Shraga; Yonit Banet-Levi; Avishay Lahad; Ifat Sarouk; Dalit Modan-Moses
Journal:  Pediatr Res       Date:  2016-02-18       Impact factor: 3.756

3.  Extracerebellar MRI-lesions in ataxia telangiectasia go along with deficiency of the GH/IGF-1 axis, markedly reduced body weight, high ataxia scores and advanced age.

Authors:  Matthias Kieslich; Franziska Hoche; Janine Reichenbach; Stefan Weidauer; Luciana Porto; Stefan Vlaho; Ralf Schubert; Stefan Zielen
Journal:  Cerebellum       Date:  2010-06       Impact factor: 3.847

Review 4.  Manganese and the Insulin-IGF Signaling Network in Huntington's Disease and Other Neurodegenerative Disorders.

Authors:  Miles R Bryan; Aaron B Bowman
Journal:  Adv Neurobiol       Date:  2017

5.  Ataxia telangiectasia mutated impacts insulin-like growth factor 1 signalling in skeletal muscle.

Authors:  James Kain Ching; Stephen H Luebbert; Roy L Collins; Zhihong Zhang; Nandhini Marupudi; Sankha Banerjee; Robin D Hurd; Lyle Ralston; Jonathan S Fisher
Journal:  Exp Physiol       Date:  2012-08-31       Impact factor: 2.969

6.  Linear growth and endocrine function in children with ataxia telangiectasia.

Authors:  Mohammad Ehlayel; Ashraf Soliman; Vincenzo De Sanctis
Journal:  Indian J Endocrinol Metab       Date:  2014-11

Review 7.  Ataxia telangiectasia: a review.

Authors:  Cynthia Rothblum-Oviatt; Jennifer Wright; Maureen A Lefton-Greif; Sharon A McGrath-Morrow; Thomas O Crawford; Howard M Lederman
Journal:  Orphanet J Rare Dis       Date:  2016-11-25       Impact factor: 4.123

8.  The impact of glutamine supplementation on the symptoms of ataxia-telangiectasia: a preclinical assessment.

Authors:  Jianmin Chen; Yanping Chen; Graham Vail; Heiman Chow; Yang Zhang; Lauren Louie; Jiali Li; Ronald P Hart; Mark R Plummer; Karl Herrup
Journal:  Mol Neurodegener       Date:  2016-08-18       Impact factor: 14.195

9.  Body composition, muscle strength and hormonal status in patients with ataxia telangiectasia: a cohort study.

Authors:  H Pommerening; S van Dullemen; M Kieslich; R Schubert; S Zielen; S Voss
Journal:  Orphanet J Rare Dis       Date:  2015-12-09       Impact factor: 4.123

10.  Atm reactivation reverses ataxia telangiectasia phenotypes in vivo.

Authors:  Sara Di Siena; Federica Campolo; Roberto Gimmelli; Chiara Di Pietro; Daniela Marazziti; Susanna Dolci; Andrea Lenzi; Andre Nussenzweig; Manuela Pellegrini
Journal:  Cell Death Dis       Date:  2018-02-22       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.